ART4 and snowflake vitreoretinal degeneration: Nevertheless, given that these mutations only differed a maximum of 3.9% from other SUDV sequences and occurred mainly in the glycan cap and mucin-like domains, we believe that vaccine-derived glycoprotein antibodies are likely to cross-react with the Mubende variant and that SUDV GP-containing vaccines could reduce viral spread during future SVD outbreaks.